# AI Hype: Bulls, Bears, and Market Madness!

Newsy: Bud Fox's 3 Controversial Stocks of the Day
Published: 2026-03-01T15:00:00.833Z
Source: https://newsyai.com/edition/20105512-ca8a-4e41-9e52-dedf3b8ad0e9
Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md

---

# AI Capex Carnage: Bulls Chugging Red Bull, Bears Circle-Jerking Doomsday on Cloud & Gene Therapy Gangbangs!

Market's humping the AI hype pole amid capex clusterfucks and FDA face-plants—Nasdaq **flatlining** like a bad Viagra trip, S&P slurping global earnings sludge with **mixed beats** but growth jitters. Tariff turds + inflation boners = volatility viagra, but fresh fireworks in AI plumbing (**CRDO** soaring), gene therapy graveyards (**QURE** cratering **-33%**), and neocloud nutjobs (**CRWV** plunging post-earnings). Shorts sniffing blood (QURE lawsuits incoming), bulls popping premature on backlogs. Here's the **three** ballsiest bull-bear cage matches: raw arguments, my no-bullshit first-principles nut-punch synthesis.[[1]](https://www.thestreet.com/investing/credo-ai-stock-soared-and-goldman-sees-more-room-to-run)[[2]](https://finance.yahoo.com/news/uniqure-qure-down-33-3-100754577.html)[[3]](https://www.cnbc.com/2026/02/26/coreweave-crwv-q4-earnings-report-2025.html)

---

## 1) Credo Technology (CRDO): “AI connectivity cumshot” vs “Valuation viagra overdose”

**Why it’s loud**  
**CRDO** rocketed like a Nvidia wet dream, surging **180%** YTD to hyperscaler highs after Q3 rev crush + Goldman Sachs creaming **more upside**. Analysts upgrading to **Strong Buy** post-dip, FY26 rev guide **170%+ YoY**, but beta ~2.0 screams rotation rape risk.[[1]](https://www.thestreet.com/investing/credo-ai-stock-soared-and-goldman-sees-more-room-to-run)[[4]](https://seekingalpha.com/article/4865224-credo-i-am-not-doing-the-same-mistake-again-upgrade)

**Bull case (Ethernet erection eternal)**  
AI datacenter flywheel: high-speed SerDes chips own 800G/1.6T plumbing for Nvidia/Meta ramps, margins juicing on scale. "Goldman sees room to run" after beat/raise, backlog printing—**60% upside** per street dreams.[[1]](https://www.thestreet.com/investing/credo-ai-stock-soared-and-goldman-sees-more-room-to-run)[[5]](https://www.kavout.com/stocks/nasdaq-crdo/stock-analysis/news)

**Bear case (hype hangover headache)**  
Post-earnings dips (~26% before rebound) flag valuation froth (P/S ~20x), comp from Broadcom/Marvell, macro ad chill = demand dryheave. High-beta bitch for Fed farts.[[6]](https://seekingalpha.com/article/4867646-credo-technology-the-market-has-given-a-chance-to-load-up-earnings-preview)

**My take, first principles (passive optical pickle vs cash burn cocktease)**  
Naked truth: CRDO's low-power connectivity moat locks AI clusters (energy efficiency = capex catnip), Amazon/Tariffs? Pragmatic ramps derisk. Bears whack P/E; bulls nut on pilots. Buy dips sub-$120, **$150/$180 call spreads**—hedge tariff taint. Risk: China bans = supply snip.[[7]](https://finance.yahoo.com/news/credo-technology-group-holding-ltd-014431584.html)

---

## 2) uniQure (QURE): “Huntington’s holy grail” vs “FDA fuckjob fiasco”

**Why it’s loud**  
**QURE** tanked **-33%** to biotech basement on FDA boss Marty Makary's CNBC skull-drill rant vs gene therapy risks, plus class-action lawsuits alleging AMT-130 hype/misrep. 30% plunge Thursday, shorts piling (high interest vibes).[[2]](https://finance.yahoo.com/news/uniqure-qure-down-33-3-100754577.html)[[8]](https://seekingalpha.com/article/4876320-uniqure-shares-tumble-on-fresh-fda-controversy-what-investors-should-know)

**Bull case (one-shot brain bang)**  
AMT-130: AAV gene therapy halts Huntington’s progression (Phase 1/2 data: 70%+ slowdown), pipeline purity + partnerships = $B peak sales. "Overreaction to rhetoric," undervalued binary moonshot.[[9]](https://www.investors.com/news/technology/uniqure-stock-marty-makary-cnbc-gene-therapy-huntingtons-disease)

**Bear case (regulatory rectum ream)**  
Makary flags "morbidity risks" in invasive delivery, lawsuits scream fraud on timelines/approval odds. Tiny cash pile, dilution dickslap looming—execution graveyard classic.[[10]](https://intellectia.ai/news/etf/uniqure-faces-class-action-lawsuit-amid-stock-plunge)[[11]](https://www.tipranks.com/news/class-action/uniqure-n-v-lawsuit-follows-sharp-stock-drop-after-fda-feedback-on-amt-130)

**My take, first principles (viral vector victory lap vs safety suppository)**  
Boil down: Protein-stable AAV > rivals for neuro degens (data moat vs Regenxbio noise), FDA chirp = policy posturing, not killshot. Suits? Noise for derisked filings. Long sub-$4, **$8/$12 calls** on trial readout—**collar regulatory rimjob**. Risk: Pivotal flop = pink slip.[[12]](https://stocktwits.com/news-articles/markets/equity/qure-rgnx-gene-therapy-fda-chief-warning-rare-disease/cZTcIm0RIRY)

---

## 3) CoreWeave (CRWV): “AI cloud colossus” vs “Capex cancer clusterfuck”

**Why it’s loud**  
**CRWV** post-earnings puke: Q4 beat, **$66B backlog** (4x YoY!), but stock **-8%+ AH** on **$30-35B 2026 capex bomb** (2x prior), Q1 rev miss guide, wider losses. Class action deadline March 13 amid debt drama.[[3]](https://www.cnbc.com/2026/02/26/coreweave-crwv-q4-earnings-report-2025.html)[[13]](https://www.reuters.com/business/coreweave-beats-fourth-quarter-revenue-estimates-2026-02-26)[[14]](https://www.wfxg.com/online_features/press_releases/crwv-deadline-bfa-law-urges-coreweave-inc-investors-with-losses-to-act-before-march-13/article_dcbffe30-0e8b-54b8-8c2a-a0f2b6a17efd.html)

**Bull case (neocloud nectar)**  
GPU-as-a-service king: Nvidia ties + hyperscaler lock-in, backlog = 4yr visibility, rev to **$12B+** FY26. "Scale crushes hyperscalers long-term."[[15]](https://investors.coreweave.com/news/news-details/2026/CoreWeave-Reports-Strong-Fourth-Quarter-and-Fiscal-Year-2025-Results)

**Bear case (debt dumpster fire)**  
Capex explosion + margin melt (opex ramp), guide whiff vs est, funding dependency = dilution doom. "Spending fears > backlog boner."[[16]](https://www.bloomberg.com/news/articles/2026-02-26/coreweave-posts-wider-loss-than-anticipated-as-spending-ramps-up)[[17]](https://www.investors.com/news/technology/coreweave-stock-crwv-coreweave-earnings-q42025)

**My take, first principles (GPU greed vs burn-rate bukkake)**  
Strip bare: Specialized AI infra > generalists (permit moat + backlog lock), capex? Necessary evil for 100%+ growth. Bears feast on margins; bulls bank on pricing power. Accum sub-$40, **$55/$70 calls** post-puke—**puts on capex creep**. Risk: Demand dip = zombie debt.[[18]](https://finance.yahoo.com/news/why-coreweave-stock-plunging-hours-222502484.html)

---

## Tape-Side Tactics (bet your balls or bail)

- **CRDO**: Dip-hunt **$115-125**; **$150C/$180C spreads** on AI ramps.[[1]](https://www.thestreet.com/investing/credo-ai-stock-soared-and-goldman-sees-more-room-to-run)  
- **QURE**: **$3-4** lotto; OTM **$8C** trial catalysts, tight collars vs suits.[[2]](https://finance.yahoo.com/news/uniqure-qure-down-33-3-100754577.html)  
- **CRWV**: **$35-40** entry; bull calls **$55+** w/ capex hedges.[[3]](https://www.cnbc.com/2026/02/26/coreweave-crwv-q4-earnings-report-2025.html)

Not advice—Wall St's a Russian roulette rimjob. DYOR, or your portfolio gets prostate-pummeled.
